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Abstract 
Objective: To determine whether baseline levels or intervention-associated changes in total and high molecular weight (HMW) 
adiponectin levels were associated with insulin resistance after six months of behavioral treatment for weight loss.  
Design: An ancillary study to a behavioral weight loss trial; the intervention was delivered in group sessions.  
Methods: Participants included 143 overweight/obese adults with a mean BMI of 33.7 kg/m2. The sample was 88% female, 67% 
white, and 44.2 ± 8.5 years old. Circulating adiponectin levels (total and HMW) and the homeostasis model assessment (HOMA) 
of insulin resistance were measured and evaluated.  
Results: At baseline, there was significant inverse associations between total adiponectin and HOMA (p < 0.001) and between 
HMW adiponectin and HOMA (p < 0.001) independent of weight. At 6-mo, there was a 17% improvement in HOMA, 8% 
increase in total adiponectin, 17% increase in HMW adiponectin levels, and 8.72% weight loss (p's for all< 0.001). There was 
also a significant inverse association between changes in total adiponectin and HOMA (p = 0.04) that was independent of 
baseline weight and weight loss. In contrast, the association between changes in HMW adiponectin and HOMA was attenuated 
after adjustment for weight loss.  
Conclusions: An increased level of total adiponectin was associated with improved insulin sensitivity, regardless of baseline 
weight and weight loss. However, baseline total and HMW adiponectin levels were more strongly associated with HOMA than 
changes in these measures at six months. HMW adiponectin level was not related more closely to insulin resistance than total 
adiponectin level.  
Keywords: Adiponectin, high molecular weight adiponectin, insulin resistance, homeostasis model assessment of insulin 
resistance (HOMA), weight loss and adiponectin levels 
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Research 
Obesity is a significant public health problem 
with recent data indicating more than 1.4 billion 
overweight adults worldwide and nearly two-thirds of 
the global population living in countries where 
overweight and obesity affect mortality more than 
underweight.
1
 As obesity is a major risk factor for the 
development of insulin resistance (IR) and associated 
metabolic diseases including hypertension, 
hyperlipidemia, atherosclerosis, and certain types of 
cancer, significant research has been conducted to 
understand obesity mechanisms related to pathogens of 
these diseases. It is now evident that adipose tissue is no 
longer considered an inert tissue mainly devoted to 
energy storage but is now recognized as an active 
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endocrine organ secreting several hormones and a 
diverse range of other protein factors.
2
 Adiponectin is 
one of the many hormones secreted by adipose tissue as 
the adipokine in the human body. IR and obesity are 
both associated with lower plasma adiponectin 
concentrations suggesting its important physiological 
role.
3
 Improvements in IR, glucose uptake in skeletal 
muscles and hepatic fatty acid oxidation upon 
administration of adiponectin in animal studies suggest 
that adiponectin may provide a link between adiposity, 
IR and diabetes.
4
 Figure 1 depicts a proposed 
mechanism linking adiposity and adiponectin with IR 
and diabetes. 
 
Figure 1. Proposed link among adiposity, adiponectin, 
insulin resistance and diabetes. 
 
 A strong inverse relationship between 
adiponectin and IR has been reported in population 
cross-sectional studies.
5-7
 Moreover, longitudinal data 
also suggest a relationship between lower adiponectin 
levels and the development of IR and diabetes.  In a 
study of Pima Indians, those with high adiponectin 
concentration were found to be at a lower risk of 
developing diabetes than those with a low 
concentration, suggesting a potential role of adiponectin 
in the pathogenesis of diabetes.
8
 Similarly, an inverse 
association between adiponectin and diabetes risk was 
reported among a large population of healthy women,
9
 a 
middle-aged population cohort,
10
 and adults with 
insulin-resistance.
11
 Mather et al. reported baseline 
adiponectin as a better marker of diabetes prevention 
than changes in adiponectin levels over one year in the 
Diabetes Prevention Program (DPP).
12
 However, no 
association was found between adiponectin and IR 
despite improved insulin sensitivity in response to 
weight loss among obese women,
13
 obese adults,
14
 and 
insulin resistant adults who were not diabetic.
15
 
Additionally, part of the difficulty also is that despite 
short term weight loss, successful long-term weight loss 
maintenance is extremely difficult as most individuals 
regain most of their weight with a few years.
16
 Because 
of these variations due to population, sample size, 
differences in baseline degree of insulin resistance, and 
adiponectin, the evidence provided by these studies on 
the relationship between IR and adiponectin in the 
presence of weight loss remains equivocal. 
Adiponectin exists in circulation in three 
distinct forms: low molecular weight (LMW), medium 
molecular weight (MMW), and high molecular weight 
(HMW) forms.
3,17
 HMW adiponectin has been 
suggested to be the most active form of adiponectin and 
more closely associated with IR with an ability to 
enhance insulin action.
18,19
 However, a major limitation 
of many epidemiological and intervention studies is the 
measurement of only total adiponectin level. Thus, little 
is known about how the relationship between HMW 
adiponectin and IR might differ from the relationship 
between total adiponectin and IR. Hence, the aims of 
this study were to determine whether baseline levels or 
intervention-associated changes in total and HMW 
adiponectin levels were associated with IR after 6 
months of behavioral treatment for weight loss.  
 
Materials and Methods 
Study design  
This was an ancillary study to the PREFER 
trial, an 18-month behavioral weight loss study designed 
to evaluate the effects of treatment preference 
(Preference-Yes vs. Preference-No) and two dietary 
treatment options, standard calorie restricted low fat diet 
(STD-D)  vs. lacto-ovo-vegetarian diet (LOV-D). 
Participants were randomly assigned first to one of the 
two preference conditions (yes or no). If assigned to the 
Preference-No condition, they were further randomly 
assigned to one of the two diet conditions, STD-D or 
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LOV-D. If assigned to Preference-Yes condition, they 
were assigned to the diet they indicated as preferred at 
screening. The design, recruitment, and randomization 
procedures for the PREFER trial have been described in 
detail elsewhere.
20
 Refer to Figure 2 for the number of 
participants at each stage. The study protocol was 
approved by the University of Pittsburgh Institutional 
Review Board; all participants provided written 
informed consent. The PREFER trial was conducted 
between 2000 and 2005, and unthawed aliquots of 
serum samples were stored at -80
0
C. The current 
analysis was limited to the 143 participants whose sera 
samples were available from baseline and 6-month 
assessments.  
 
Figure 2. PREFER trial flowchart (included only 6-mo 
assessment). 
 
Participants  
The study population included adults between 
18 and 55 years of age, a body mass index (BMI) 
between 27 and 43 kg/m
2
 inclusively, and adequately 
completed a 5-day food diary at screening. Individuals 
were excluded if they had diabetes or a medical 
condition requiring physician supervision of diet or 
physical activity, were pregnant, participated in a 
behavioral or pharmacological weight-loss program in 
the last 6 months, reported alcohol intake of  ≥ 4 drinks 
per day, and reported abstention from eating meat, 
poultry, or fish in the past month.  
 
Intervention  
All four treatment groups received the same 
standard behavioral intervention. The only difference 
between the diet groups was that the LOV-D 
participants were instructed to eliminate meat, poultry, 
and fish form their diet by the 6th week of the program. 
Details of the intervention have been reported 
elsewhere.
20
 In brief, all participants received a daily 
energy and fat gram goal based on gender and baseline 
body weight as described in Table 1. Participants were 
instructed to increase their physical activity gradually, 
primarily via walking, until they reached a goal of 150 
minutes by week 6. As an alternative to walking, 
aerobic activities such as bicycling, swimming, and 
jogging were encouraged. Use of frequent, short bouts 
to meet one’s exercise goal, for example exercising for 
10–15 minutes three times per day, was also promoted. 
The intervention group sessions were held weekly 
during the first six months. The cognitive-behavioral 
intervention used several strategies from models of 
motivation and behavior change. All participants 
received nutritional and behavioral counseling and were 
provided with practical hands-on experience to develop 
skills to implement a healthy lifestyle. All participants 
self-monitored their daily energy and fat intake, as well 
as physical activity (duration and type) they performed 
during the study period.  
 
Table 1. Daily dietary goals. 
 
Measures  
Baseline demographic characteristics were 
collected via a self-administered, standardized 
questionnaire. All anthropometric, biochemical, and 
adiponectin measurements were obtained at baseline 
and 6 months. Weight was measured on a digital scale 
(Tanita Corporation of America, Inc., IL) in 
light clothing and without shoes. Height was measured 
with a wall-mounted stadiometer. The physical activity 
assessment was conducted via a self-administered 
Paffenbarger Activity Questionnaire.
21
 This 
questionnaire has been shown to have good test-retest 
reliability. A metabolic equivalent value was assigned to 
each leisure activity, from which the total energy 
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expenditure was calculated. Blood samples, obtained 
following a 12-hour fast were assayed at the Heinz 
Nutrition Laboratory, University of Pittsburgh. Plasma 
glucose was measured with the use of the hexokinase-
glucose 6-phosphate dehydrogenase enzymatic assay 
(Sigma Diagnostics, St. Louis, MO), and insulin 
concentration was measured by a radioimmunoassay kit 
(Linco Research, St. Charles, MO). Insulin resistance 
was assessed by homeostasis model assessment of 
insulin resistance (HOMA-IR) and was calculated as 
fasting insulin concentration (U/mL) x fasting glucose 
concentration (mmol/L)/22.5. HOMA is a mathematical 
assessment of the balance between hepatic glucose 
output and insulin secretion and has been widely 
validated and applied for quantifying insulin resistance 
and β-cell function. Serum levels of total and HMW 
adiponectin were determined using the ELISA 
technique (ALPCO Diagnostics, Salem, NH). The intra-
assay and inter-assay CVs were 6.4% and 12.7% for 
total adiponectin and 6.4% and 12.6% for HMW 
adiponectin, respectively. All samples were assayed in 
duplicate.   
 
Statistical analysis  
Statistical analyses were performed using SAS 
(version 9.2; SAS Institute Inc, Cary, NC). All 
continuous variables were checked for normality. Basic 
statistics were expressed as mean ± SD or as 
proportions, unless otherwise specified. For all 
continuous variables, comparisons between baseline and 
6-month measures were examined using a paired 
sample’s t-test. A chi-square test was performed for 
comparing the categorical variables at baseline. 
Associations between continuous variables were 
assessed using the Pearson or Spearman correlation 
coefficient. Separate multiple linear regression models 
were used for HOMA at baseline and change in HOMA 
score (6-month – baseline scores) as the dependent 
variables to examine associations between total and 
HMW adiponectin at baseline and 6 months. The 
models were adjusted for age, gender, race, baseline 
weight, baseline energy expenditure, changes in weight, 
and energy expenditure. All tests performed were two-
sided, and significance level was set at p < 0.05. 
 
Results 
Of the 176 participants randomized at baseline, 
151 completed the 6-month assessment, and the sera 
samples of 143 (95%) participants were available from 
both baseline and 6-month assessments. The majority of 
participants were female (88%), white (67%), currently 
married or living with a partner (65%), and employed 
(94%). The mean age was 44.2 ± 8.5 years old with a 
BMI range of 26.71 to 42.56 kg/m
2 
(Mean= 33.78 
kg/m
2
) and, on average, 15.3 years of formal education. 
No differences in baseline characteristics were found 
between participants who were excluded and those 
included in the analysis. There was no significant 
difference in HOMA between the two diet groups; STD-
D vs. LOV-D (4.28 ± 2.15 vs. 4.62 ± 2.32; p = 0.3), nor 
were there differences by the two preference groups; 
Preference-Yes vs. Preference-No (4.60 ± 2.18 vs. 4.28 
± 2.27; p = 0.4). Additionally, there were no significant 
differences in total adiponectin level by diet group (7.82 
± 3.74 vs. 7.64 ± 2.87 ug/ml; p = 0.7) or preference 
group (7.76 ± 3.57 vs. 7.62 ± 7.66 ug/ml; p = 0.7), nor 
did HMW adiponectin level differ by diet group (3.33 ± 
2.21 vs. 3.23 ± 1.68 ug/ml; p = 0.8) or preference group 
(3.30 ± 1.97 vs. 3.23 ± 20.01; p = 0.8). Since there were 
no significant differences between the two diet groups 
and the two preference groups, further analyses were 
conducted as a single sample without regard to 
randomized diet or preference condition.  
At baseline, HOMA did not differ by gender 
(female vs. male: 4.36 ± 2.23 vs. 4.97 ± 2.24; p = 0.3) or 
race (white vs. non-white: 4.47 ± 2.34 vs. 4.33 ± 20.00; 
p = 0.7). However, females had significantly higher 
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total (7.85 ± 3.32 vs. 6.31 ± 2.58 ug/ml; p = 0.04) and 
HMW adiponectin levels (3.37 ± 2.9 vs. 2.39 ± 1.43 
ug/ml; p = 0.03) than males. Figure 3 describes the 
baseline and 6-month measures of the studied variables. 
From baseline to 6 months, there was a 17% reduction 
in HOMA (p < 0.001), 8% increase in total adiponectin 
(p = 0.001), and 17% increase in HMW adiponectin 
levels (p < 0.001). Further, there was a significant 
weight loss (8.72%) at 6 months (p < 0.001). There 
were highly significant correlations between total and 
HMW adiponectin levels at baseline (r = 0.95; p < 
0.001) and also at 6 months (r = 0.95; p < 0.001). At 
baseline and 6 months, weight, BMI, glucose, and 
insulin showed significant positive associations with the 
HOMA score while total and HMW adiponectin levels 
showed significant negative association with HOMA (p 
for all < 0.001).  
 
Figure 3. Measures at baseline and 6-month 
assessments. 
 
Separate multiple regression analyses were 
performed for both baseline and 6-month measures with 
baseline HOMA and the change in HOMA scores as the 
dependent variables, respectively. The final model, with 
baseline measures adjusted for weight, indicated 
significant inverse associations between total 
adiponectin and the HOMA score (p < 0.001) and 
between HMW adiponectin and HOMA (p < 0.001). 
The estimates for total and HMW adiponectin still 
remained highly significant after adjustment for baseline 
weight (Table 2). At 6 months, the final regression 
model revealed a significant inverse association 
between changes in total adiponectin and HOMA (p = 
0.04) that was independent of baseline weight and 
weight loss. In contrast, higher HMW adiponectin was 
associated with improvements in the HOMA score 
without weight loss in the model (p = 0.02), but the 
association was no longer significant after adjustment 
for weight loss (Table 3). Additional adjustment for 
energy expenditure at baseline and 6 months did not 
alter the results.  
 
Table 2:  Multiple regression models of total and HMW 
adiponectin levels on baseline HOMA measure (N = 
143). 
 
Table 3: Multiple regression models of total and HMW 
adiponectin levels on change in HOMA measure at 6 
months (N = 143). 
 
Discussion 
A better understanding of the extent of the 
association of adiponectin with IR in obesity might help 
clarify mechanisms of insulin sensitivity, which in turn, 
might be beneficial in identifying preventive approaches 
to enhance insulin sensitivity and thereby reduce the 
risk for developing diabetes. The study's findings 
revealed that the higher baseline levels of total and 
HMW adiponectin levels were significantly associated 
with lower HOMA score, independent of body weight. 
At 6 months there were significant reductions in the 
HOMA score and weight, which paralleled the 
improvements in total and HMW adiponectin levels. 
The increase in total adiponectin was inversely 
associated with a decrease in the HOMA score 
independent of baseline weight and weight change. 
However, the significant association between changes in 
HMW adiponectin level and the HOMA score was 
attenuated after adjustment for weight change.   
There were significant inverse associations of 
total and HMW adiponectin levels with the HOMA 
score at baseline, even after adjusting for baseline 
weight, indicating an independent association of total 
and HMW adiponectin levels with the HOMA score 
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regardless of the degree of obesity. The association 
between total adiponectin and HOMA is consistent with 
findings from previous studies among individuals with 
type 2 diabetes,
22
  a representative community adult 
population,
6
 and a community-based cohort with and 
without the metabolic syndrome.
5
 The DPP study also 
reported an inverse association between baseline total 
adiponectin levels and future diabetes independent of 
baseline adiposity among individuals at increased risk 
for diabetes.
12
 The findings suggest the persistence of an 
independent role of not only total adiponectin but also 
HMW adiponectin levels in relation to IR among a 
generally healthy overweight/obese population with no 
diabetes or clinical vascular disease.  
The association between changes in total and 
HMW adiponectin levels and HOMA scores were 
examined separately after 6 months of intervention. The 
degree of univariate association between HOMA and 
total and HMW adiponectin levels at both baseline and 
6 months remained unchanged. There were 
intervention-associated significant reductions in weight, 
the HOMA score and improvements in total, and HMW 
adiponectin levels. The increase in total and HMW 
adiponectin was associated with the change in weight 
suggesting that change in total and HMW adiponectin 
levels might reflect body weight change. The multiple 
regression analysis showed that an increased level of 
total adiponectin contributed to improved insulin 
sensitivity independent of baseline weight and change in 
weight. Although the estimate for change in total 
adiponectin decreased by 34% when change in weight 
was added to the model, these results indicate that 
improvements in total adiponectin level contributed to 
improved insulin sensitivity above the usual clinical 
markers of diabetes. The present study highlights the 
importance of adiponectin in the development of IR and 
subsequent development of Type 2 diabetes. Thus, 
interventions, such as the one used in this study, that 
target weight loss and increase total adiponectin levels 
may improve insulin sensitivity and reduce the risk of 
diabetes for overweight individuals.  
A few studies have reported HMW adiponectin 
to have a stronger association than total adiponectin 
level in the incidence of type 2 diabetes
23,24
 and insulin 
sensitivity.
17-19,25
 Most of these studies either had only a 
single measurement of HMW adiponectin level,
19,23-25
 
were limited by the small sample size,
15,17,18
 or had a 
pharmacological intervention.
26
 There was a highly 
significant association between total and HMW at 
baseline. Bluher et al. reported no superiority of HMW 
adiponectin over total adiponectin values in predicting 
insulin sensitivity.
27
 Likewise, the study results also 
showed a similar magnitude of correlations between 
both total and HMW adiponectin levels with the HOMA 
score at baseline suggesting no clinical differences 
between total and HMW adiponectin levels in relation 
to insulin resistance.  
At 6 months, the significant association 
between changes in HMW adiponectin level and 
HOMA was attenuated after adjustment for change in 
weight and was no longer significant, despite an 
increase in HMW adiponectin that was more than 
double the increase in total adiponectin. This finding 
indicates a possible threshold level of HMW 
adiponectin that might be needed to have an 
independent effect on change in the HOMA score. 
Alternatively, a different pathway of an intervention-
associated change in HMW adiponectin level from the 
baseline HMW adiponectin level could not be ruled out 
as a possibility. Regardless of the mechanism, the study 
refutes the hypothesis of a predominant role of HMW 
adiponectin level over total adiponectin level in relation 
to IR. The study also provided a unique opportunity to 
examine if baseline or intervention associated changes 
in total and HMW adiponectin levels were more 
strongly associated with IR. The degree of association 
between total and HMW adiponectin level were 
stronger at baseline than the relationship between 
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changes in total adiponectin and the HOMA score at 6 
months. Moreover, the significant association between 
change in HMW adiponectin level and HOMA score 
was taken over by weight loss. Consistent with the 
findings of Mather et al.,
12
 baseline total and HMW 
adiponectin levels were more closely related to IR than 
the changes in these measures at 6 months. 
The potential mechanism of how plasma 
adiponectin levels influence IR is still not known. A 
higher level of adiponectin level has been reported to 
increase fatty acid oxidation with subsequent reduction 
of triglycerides thereby directly sensitizing the body to 
insulin and reserving IR in animal models of obesity 
and diabetes
28
 and in humans.
25
 Through in vitro 
studies, adiponectin has been shown to trigger the 
protein kinase, an insulin independent enzyme known to 
stimulate glucose use and increase fatty acid oxidation 
in skeletal muscle.
4
 It has been reported that some 
inflammatory markers, such as tumor necrosis factor-α, 
interleukin-6 or C-reactive protein have an adiponectin 
inhibitory effect, which in turn may lead to IR.
7,29
 It is 
possible that the levels of these markers decrease with 
the corresponding increase in adiponectin levels with 
weight loss and may improve insulin sensitivity.  
A main limitation of the study included a 
measure of IR with a surrogate marker. However, 
HOMA derived from the mathematical model has been 
shown to be an adequate indicator of IR and has been 
used in many epidemiological and clinical studies. Also, 
the generalizability of these findings may be limited due 
to the relatively homogenous study population; 
however, the minority representation exceeded that of 
the local community. The strengths of the study 
included the measurements of both total and HMW 
adiponectin. An additional strength was its longitudinal 
design and examination of the relationship between total 
and HMW adiponectin levels with IR cross-sectionally 
and over time. Moreover, the clinical measures were 
obtained via a standardized protocol and assays were 
performed with good precision and the study included a 
larger sample than what has been reported in the 
literature. 
 
Conclusions 
An increased level of total adiponectin 
contributed to improved insulin sensitivity regardless of 
baseline weight and weight loss. However, the 
association of change in total adiponectin and HOMA 
score was modest compared to baseline measures 
suggesting that the cross-sectional measure of total 
adiponectin might be a comparable indicator of IR and 
subsequent risk of developing diabetes among 
overweight or obese adults.  These findings provide 
support for the importance of adiponectin levels and a 
need for their improvements to prevent diabetes.  Thus, 
interventions that enhance adiponectin secretion or 
action may have potential for diabetes risk reduction. 
Improvements in the HMW adiponectin level were 
largely explained by the weight loss suggesting the role 
of HMW adiponectin level is no more important than 
that of total adiponectin in relation to improved insulin 
sensitivity. These findings provide evidence for the 
importance of weight loss as a significant public health 
preventive measure to enhance adiponectin levels 
among the studied population, which could impact the 
progression of atherosclerosis and associated metabolic 
diseases. 
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Table 1. Daily dietary goals. 
Baseline  
weight (lbs) 
Prescribed daily goals 
Energy intake  
(kcal) 
Total fat intake 
(g)* 
Male Female Male Female 
< 200 1500 1200 42 33 
≥ 200 1800 1500 50 42 
     * 25% of the total energy intake for everyone.  
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Table 2:  Multiple regression models of total and HMW adiponectin levels on baseline HOMA measure (N = 143). 
Models Baseline HOMA R
2
 Models Baseline HOMA R
2
 
Estimate s.e. P Estimate s.e. P 
Model 1 
    Adiponectin (ug/ml) 
 
-0.28 
 
0.05 
 
< 0.001 
 
0.17 
Model 1 
   HMW (ug/ml) 
 
-0.42 
 
0.09 
 
< 0.001 
 
0.14 
Model 2  
   Adiponectin (ug/ml) 
   Gender 
   Race 
   Age (yr) 
 
-0.29 
-0.12 
-0.40 
-0.02 
 
0.05 
0.55 
0.37 
0.02 
 
< 0.001 
0.83 
0.28 
0.27 
 
0.18 
Model 2 
   HMW (ug/ml) 
   Gender 
   Race 
   Age (yr) 
 
-0.45 
-0.10 
-0.52 
0.01 
 
0.09 
0.56 
0.38 
0.02 
 
< 0.001 
0.85 
0.17 
0.40 
 
0.15 
Model 3 
   Adiponectin (ug/ml) 
   Gender 
   Race 
   Age (yr) 
   Weight (kg)  
 
-0.26 
0.45 
-0.46 
0.02 
0.06 
 
0.05 
0.34 
0.01 
0.02 
0.01 
 
< 0.001 
0.39 
0.18 
0.20 
< 0.001 
 
0.30 
Model 3 
   HMW (ug/ml) 
   Gender 
   Race 
   Age (yr) 
   Weight (kg) 
 
-0.38 
0.44 
0.55 
0.02 
0.06 
 
0.09 
0.54 
0.36 
0.02 
0.01 
 
< 0.001 
0.42 
0.12 
0.32 
< 0.001 
 
0.27 
HMW= high molecular weight; HOMA= homoeostasis model assessment of insulin resistance. 
Reference groups: gender-males, race- white 
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Table 3: Multiple regression models of total and HMW adiponectin levels on change in HOMA measure at 6 months (N = 143). 
Models Change in  HOMA R
2
 Models Change in  HOMA R
2
 
Estimate s.e. P Estimate s.e. P 
Model 1 
   Adiponectin Δ (ug/ml) 
 
-0.25 
 
0.09 
 
0.004 
 
0.06 
Model 1 
   HMW Δ (ug/ml) 
 
-0.34 
 
0.14 
 
0.02 
 
0.04 
Model 2  
   Adiponectin Δ (ug/ml) 
   Gender 
   Race 
   Age (yr) 
 
-0.25 
0.95 
0.38 
0.01 
 
0.08 
0.43 
0.29 
0.01 
 
0.005 
0.03 
0.20 
0.9 
 
0.11 
Model 2  
   HMW Δ (ug/ml) 
   Gender 
   Race 
   Age (yr) 
 
-0.32 
  0.99 
  0.33 
  0.0003 
 
0.15 
0.43 
0.30 
0.01 
 
0.03 
0.02 
0.28 
0.98 
 
0.09 
Model 3 
   Adiponectin Δ (ug/ml) 
   Gender 
   Race 
   Age (yr) 
   Baseline weight (kg)  
 
-0.26 
0.64 
0.44 
-0.000 
-0.03 
 
0.09 
0.43 
0.29 
0.02 
0.009 
 
0.003 
0.14 
0.13 
0.97 
0.003 
 
0.16 
Model 3 
   HMW Δ (ug/ml) 
   Gender 
   Race 
   Age (yr) 
   Baseline weight (kg)  
 
-0.34 
0.68 
0.38 
-0.001 
-0.03 
 
0.15 
0.44 
0.29 
0.02 
0.009 
 
0.02 
0.12 
0.19 
0.92 
0.003 
 
0.14 
Model 4 
   Adiponectin Δ (ug/ml) 
   Gender 
   Race 
   Age (yr) 
   Baseline weight (kg) 
   Weight Δ (kg) 
 
-0.17 
0.06 
0.46 
0.0005 
-0.03 
0.10 
 
0.08 
0.42 
0.27 
0.01 
0.009 
0.02 
 
0.04 
0.88 
0.09 
0.97 
0.005 
< 0.0001 
 
0.27 
Model 4 
   HMW Δ (ug/ml) 
   Gender 
   Race 
   Age (yr) 
   Baseline weight (kg) 
   Weight Δ (kg) 
 
-0.18 
0.10 
0.40 
0.000 
-0.02 
0.10 
 
0.14 
0.48 
0.27 
0.01 
0.008 
0.02 
 
0.21 
0.82 
0.14 
0.99 
0.006 
< 0.0001 
 
0.26 
HMW=high molecular weight; HOMA= homoeostasis model assessment of insulin resistance; Δ=change. 
Changes values were defined as 6 months - baseline.  
Reference groups: gender-males, race- white  
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Figure 1. Proposed link among adiposity, adiponectin, insulin resistance and diabetes. 
Obesity 
 
↑ Adiposity 
 
↓ Adiponectin 
 
 
↓ Glucose uptake ↑ Gluconeogenesis 
(muscle)  (liver) 
 
 
Insulin Resistance 
 
 
Diabetes 
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Figure 2. PREFER trial flowchart (included only 6-mo assessment). 
 
 
  
Screened for eligibility by phone (n=932) 
Sent screening packets (n=425) 
Returned 5-Day Food Diary (n=218) 
Invited to Information Session (n=298) 
Attended Baseline Assessment 
(n=204) 
Randomized (n=200) 
PREFER - NO PREFER - YES 
SBT (n=48) 
Completed 6-month 
assessment 
(n=42, 87.5%) 
SBT+LOV (n=35) 
Completed 6-
month assessment       
(n=29, 82.9%) 
 
 
(n=29, 82.9%) 
 
(n=29, 82.9%) 
SBT (n=48) 
Completed 6-month 
assessment         
(n=41, 85.4%) 
 
(n=41, 85.4%) 
SBT+LOV (n=45) 
Completed 6-month 
assessment         
(n=39, 86.7%) 
 
(n=39, 86.7%) 
Discarded (n=15) 
Ineligible (n=9) 
Included in this ancillary study (N=143)* 
STD-D = Standard Diet; LOV-D = Lacto-Ovo-Vegetarian Diet 
*Blood samples on 94.7% of participants who attended the 6-mo assessment were 
stored and analyzed 
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Figure 3. Measures at baseline and 6-month assessments. 
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